ViewRay, Inc. (VRAYQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ViewRay, Inc. (VRAYQ) trades at $0.00 with AI Score 60/100 (Grade B+). ViewRay, Inc. is a healthcare company specializing in MRI-guided radiation therapy systems for cancer treatment. Market cap: $18,340, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for VRAYQ: VRAYQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRAYQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VRAYQ: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →ViewRay, Inc. (VRAYQ) Healthcare & Pipeline Overview
ViewRay, Inc. is a pioneering healthcare company focused on MRI-guided radiation therapy systems, addressing critical challenges in cancer treatment with innovative technology and a global reach in key markets.
What Is the Investment Thesis for VRAYQ?
ViewRay, Inc. is currently navigating a challenging financial landscape following its Chapter 11 bankruptcy filing, which has since transitioned to Chapter 7. The company’s innovative MRIdian system represents a significant advancement in cancer treatment technology, addressing critical issues in radiation therapy. However, with a profit margin of -105.2% and a gross margin of only 9.8%, the company faces substantial operational hurdles. The competitive landscape includes established players in the medical devices sector, making it imperative for ViewRay to either find a path to recovery or face potential liquidation. The future of ViewRay hinges on its ability to either restructure effectively or attract new investment to revive its operations, particularly in light of the growing demand for advanced cancer treatment technologies, projected to expand at a CAGR of 7.5% through 2030.
Based on FMP financials and quantitative analysis
VRAYQ Key Highlights
- Market Cap: $0.00B, indicating significant financial distress and recent bankruptcy.
- Profit Margin: -105.2%, reflecting ongoing operational losses.
- Gross Margin: 9.8%, which is below industry standards, highlighting efficiency challenges.
- Beta: 1.34, indicating higher volatility compared to the market.
- Dividend Yield: None, as the company does not currently return capital to shareholders.
Who Are VRAYQ's Competitors?
VRAYQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VAR VAR | $177.07 | +0.00% | 46 | |
| CIVI Civitas Resources, Inc. | $27.38 | -1.37% | $2.34B | 54 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| PLSM PLSM | $4.96 | +9.25% | $32.25M | 60 |
| ECOR electroCore, Inc. | $8.28 | -5.59% | $68.69M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRAYQ's Key Strengths?
- Innovative MRIdian technology that enhances treatment precision.
- Established presence in multiple international markets.
- Strong network of healthcare providers and institutions.
What Are VRAYQ's Weaknesses?
- Recent bankruptcy filing raises concerns about financial stability.
- Low gross margins indicate potential operational inefficiencies.
- Dependence on a limited product line for revenue generation.
What Could Drive VRAYQ Stock Higher?
- Potential restructuring plans post-bankruptcy could attract new investment.
- Continued demand for advanced cancer treatment technologies in global markets.
- Partnerships with healthcare providers and research institutions for clinical trials.
What Are the Key Risks for VRAYQ?
- Financial-distress signal — its Altman Z-Score of -6.12 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-85.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Ongoing financial instability and uncertainty following bankruptcy.
- Intense competition from established players in the medical devices sector.
- Regulatory challenges in various international markets affecting product sales.
What Are the Growth Opportunities for VRAYQ?
- Growth opportunity 1: The global cancer treatment market is projected to reach $200 billion by 2030, driven by an increasing prevalence of cancer and advancements in treatment technologies. ViewRay's MRIdian system, with its unique MRI-guided capabilities, could capture a significant share of this market, especially as healthcare providers seek more effective treatment options. The timeline for capturing this market opportunity hinges on the company's ability to stabilize its operations and re-establish its sales channels post-bankruptcy.
- Growth opportunity 2: The increasing focus on personalized medicine presents an opportunity for ViewRay to enhance its product offerings. By integrating artificial intelligence and machine learning into its MRI-guided systems, ViewRay could improve treatment precision and patient outcomes. This enhancement could attract new customers and retain existing ones, particularly in research and academic institutions that prioritize cutting-edge technology.
- Growth opportunity 3: Expansion into emerging markets such as Asia and Latin America could provide ViewRay with new revenue streams. These regions are experiencing a rise in cancer cases and a growing demand for advanced medical technologies. By establishing partnerships with local distributors and healthcare providers, ViewRay could effectively penetrate these markets, potentially increasing its global footprint and revenue base.
- Growth opportunity 4: Collaborations with leading research institutions for clinical trials could enhance ViewRay's credibility and product development. By demonstrating the efficacy of its MRIdian system in clinical settings, the company could attract interest from hospitals and cancer treatment centers, leading to increased sales and market acceptance. These partnerships could also facilitate access to funding and resources for further innovation.
- Growth opportunity 5: The trend towards value-based healthcare could drive demand for ViewRay's innovative solutions. As healthcare systems increasingly focus on patient outcomes and cost-effectiveness, the ability of MRIdian to reduce treatment side effects and improve patient experiences could position ViewRay favorably in negotiations with healthcare providers and payers.
What Opportunities Does VRAYQ Have?
- Growing global demand for advanced cancer treatment technologies.
- Potential for expansion into emerging markets.
- Opportunities for partnerships with research institutions.
What Threats Does VRAYQ Face?
- Intense competition from established medical device companies.
- Regulatory challenges in different international markets.
- Market volatility and economic downturns affecting healthcare spending.
What Are VRAYQ's Competitive Advantages?
- Innovative technology that combines MRI imaging with radiation therapy.
- Strong intellectual property portfolio protecting proprietary technology.
- Established relationships with key healthcare providers and institutions.
- Specialization in a niche market of MRI-guided radiation therapy.
- Potential for improved patient outcomes, enhancing customer loyalty.
What Does VRAYQ Do?
Founded in 2004 and headquartered in Denver, Colorado, ViewRay, Inc. designs, manufactures, and markets advanced magnetic resonance imaging (MRI) guided radiation therapy systems, primarily aimed at treating cancer patients. The company's flagship product, MRIdian, utilizes MRI technology to provide real-time imaging during radiation therapy, which helps mitigate issues such as beam distortion and skin toxicity, thereby enhancing treatment precision and patient outcomes. ViewRay serves a diverse clientele that includes university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers across the United States, Italy, France, Taiwan, the United Kingdom, and other international markets. Despite its innovative offerings, ViewRay has faced significant challenges, culminating in a voluntary petition for reorganization under Chapter 11 bankruptcy in July 2023, which was later converted to Chapter 7 in October 2023, indicating a critical juncture in the company's operational viability. The company has built a network of direct sales forces and distributors to effectively reach its target markets, positioning itself as a leader in the niche of MRI-guided radiation therapy. However, the recent financial difficulties raise questions about its future operational capabilities and market presence.
What Products and Services Does VRAYQ Offer?
- Design and manufacture MRI-guided radiation therapy systems.
- Market the MRIdian system for cancer treatment.
- Address beam distortion and skin toxicity in radiation therapy.
- Serve a diverse range of healthcare institutions globally.
- Utilize a network of direct sales and distributors.
- Focus on enhancing treatment precision and patient outcomes.
How Does VRAYQ Make Money?
- Revenue generated from the sale of MRI-guided radiation therapy systems.
- Ongoing service and maintenance contracts for installed systems.
- Potential revenue from partnerships and collaborations in clinical research.
- Sales through a combination of direct sales force and distribution networks.
- Focus on high-value contracts with hospitals and cancer treatment centers.
What Industry Does VRAYQ Operate In?
The medical devices industry is experiencing robust growth, driven by technological advancements and increasing demand for innovative healthcare solutions. The global market for cancer treatment technologies is projected to grow at a CAGR of 7.5%, reaching approximately $200 billion by 2030. ViewRay, Inc. operates in a competitive landscape that includes both established players and emerging companies focused on radiation therapy solutions. The shift towards personalized medicine and advanced imaging technologies positions ViewRay as a key player, although its recent financial challenges may hinder its ability to capitalize on these market trends.
Who Are VRAYQ's Key Customers?
- University research and teaching hospitals.
- Community hospitals and private practices.
- Government institutions and healthcare systems.
- Freestanding cancer centers.
- International markets including Europe and Asia.
ROE -85%Key Financial Metrics
Return on equity for ViewRay, Inc. stands at -85.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.6%, showing how much profit it generates from its asset base. A current ratio of 2.36 indicates the company holds enough short-term assets to cover its near-term obligations.
ViewRay, Inc. (VRAYQ) Valuation Context
Valued at 18K, VRAYQ is classified as a micro-cap stock. Relative to its peer group, VRAYQ's quantitative score of 60/100 is roughly in line with the peer average of 64/100.
Company Profile
ViewRay, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Denver, US. The company is led by CEO Paul Ziegler Jr.. VRAYQ has traded publicly since 2015.
F-Score 2/9Financial Health
ViewRay, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.12 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project ViewRay, Inc. revenue of about $306.4M for fiscal 2026, with EPS near $-0.06.
VRAYQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in the potential upside.
- Community sentiment has leaned positive, with discussions highlighting the innovative technology in cancer treatment that ViewRay offers.
- Recent partnerships and collaborations have been viewed favorably, as they could enhance the company's market presence and credibility.
- The increasing focus on personalized medicine aligns with ViewRay's offerings, potentially attracting more attention from investors and healthcare providers.
Bear Case
- Concerns about the competitive landscape in the medical technology sector have surfaced, with several new entrants vying for market share.
- Social sentiment has reflected skepticism regarding the company's ability to scale operations effectively amidst ongoing challenges.
- Recent earnings reports have shown that revenue growth may not meet investor expectations, leading to bearish sentiment in the community.
- The overall market volatility has raised caution among investors, with some viewing ViewRay as a high-risk investment in uncertain times.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VRAYQ Latest News
No recent news available for VRAYQ.
VRAYQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRAYQ.
Price Targets
Wall Street price target analysis for VRAYQ.
VRAYQ MoonshotScore
What does this score mean?
The MoonshotScore rates VRAYQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul Ziegler Jr.
CEO
Paul Ziegler Jr. has extensive experience in the healthcare sector, particularly in medical devices. He has held various leadership roles in companies focused on innovative healthcare solutions, bringing a wealth of knowledge in management and operational strategy. Ziegler holds a degree in engineering and has a strong background in product development and commercialization.
Track Record: Under Ziegler's leadership, ViewRay has developed its MRIdian technology and expanded its market presence, although recent financial challenges have posed significant hurdles. His strategic focus on innovation and partnerships has been critical in positioning the company within the competitive landscape of cancer treatment technologies.
VRAYQ OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements and lower visibility in the market, which can affect liquidity and investor confidence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial reporting and transparency due to bankruptcy proceedings.
- Potential for significant price volatility given the company's financial distress.
- Lower investor confidence in OTC stocks compared to those on major exchanges.
- Review recent financial statements and bankruptcy filings.
- Assess the company's market position and competitive landscape.
- Evaluate management's track record and strategic plans for recovery.
- Investigate any ongoing litigation or regulatory issues.
- Confirm the company's ability to continue operations post-bankruptcy.
- Established history since 2004 in the medical device sector.
- Innovative technology with potential applications in cancer treatment.
- Partnerships with recognized healthcare institutions and research organizations.
What Investors Ask About ViewRay, Inc. (VRAYQ) — Healthcare
What does ViewRay, Inc. do?
ViewRay, Inc. specializes in designing and manufacturing MRI-guided radiation therapy systems, primarily targeting cancer treatment. Its flagship product, MRIdian, utilizes advanced MRI technology to provide real-time imaging during radiation therapy, enhancing treatment precision and minimizing side effects. The company serves a diverse range of healthcare institutions globally, including hospitals and cancer centers.
What are the main risks for VRAYQ?
ViewRay faces several significant risks, including ongoing financial instability due to its recent bankruptcy filing, which raises concerns about its operational viability. Additionally, the company operates in a highly competitive medical device market, where established players may overshadow its offerings. Regulatory challenges in different international markets could also hinder its ability to sell products effectively, further complicating its recovery efforts.
What revenue streams does ViewRay, Inc. have in healthcare?
ViewRay generates revenue primarily through the sale of its MRI-guided radiation therapy systems, particularly the MRIdian system. Additionally, the company earns income from ongoing service and maintenance contracts for installed systems. Potential revenue could also arise from partnerships and collaborations in clinical research, as well as sales through its network of direct sales and distributors targeting hospitals and cancer treatment centers.
What are the key factors to evaluate for VRAYQ?
ViewRay, Inc. (VRAYQ) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does VRAYQ data refresh on this page?
VRAYQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VRAYQ's recent stock price performance?
ViewRay, Inc. (VRAYQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative MRIdian technology that enhances treatment precision. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRAYQ overvalued or undervalued right now?
Valuing ViewRay, Inc. (VRAYQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VRAYQ?
Before investing in ViewRay, Inc. (VRAYQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Company is currently in bankruptcy proceedings, impacting financial transparency.